Ligand Pharmaceuticals/ US53220K5048 /
| 11/8/2024 9:59:40 PM | Chg. -8.65 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 121.12USD | -6.66% | 11,237 Turnover: 1.35 mill. |
-Bid Size: - | -Ask Size: - | 2.22 bill.USD | - | 40.15 |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | 3.02 USD | - |
| EPS Diluted: | 2.94 USD | - |
| Revenues per Share: | 7.42 USD | -35.46% |
| Book Value per Share: | 39.59 USD | 13.15% |
| Cash Flow per Share: | 2.80 USD | -65.31% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 131.31 USD | -33.09% |
| Net Income: | 52.15 USD | - |
| Operating Cash Flow: | 49.58 USD | - |
| Cash and Cash Equivalents: | 22.95 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | 40.15 | 23.65 |
| P/S Ratio: | 16.35 | 9.63 |
| P/BV ratio: | 3.06 | 1.80 |
| P/CF Ratio: | 43.30 | 25.51 |
| PEG: | - | - |
| Earnings Yield: | 2.49% | 4.23% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 2.22 bill. USD | 1.26 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 18.27 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | 9.09% |
| Net Profit Margin: | 39.72% |
| Return on Equity: | 7.44% |
| Return on Assets: | 6.63% |
Financial Strength
| Liquidity I / Cash Ratio: | 1.37% |
| Liquidity II / Quick Ratio: | 3.33% |
| Liquidity III / Current Ratio: | 14.15% |
| Debt / Equity Ratio: | 0.00% |
| Dynam. Debt / Equity Ratio: | 174.08% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 12/31/2023 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
